Henry Nasrallah, MD
Psychiatry · Cincinnati, OHNPI 1346386307
Payments from drug & device makers
Across 3,546 payments — averaging $1062.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$694K
- Teva Pharmaceuticals USA, Inc.$526K
- Neurocrine Biosciences, Inc.$488K
- Otsuka America Pharmaceutical, Inc.$417K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$411K
- Axsome Therapeutics, Inc.$291K
- plus $942K from 15 others
What the payments were for
- Consulting fees$480,22213%
- Speaking & faculty fees$2,757,31673%
- Travel & lodging$473,46413%
- Food & beverage$58,0402%
- Education$2650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 631 | $693,719 |
| Teva Pharmaceuticals USA, Inc. | 410 | $525,970 |
| Neurocrine Biosciences, Inc. | 476 | $488,130 |
| Otsuka America Pharmaceutical, Inc. | 553 | $416,976 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 338 | $411,274 |
| Axsome Therapeutics, Inc. | 259 | $291,190 |
| Alkermes, Inc. | 284 | $280,167 |
| E.r. Squibb & Sons, L.L.C. | 126 | $185,331 |
| Acadia Pharmaceuticals Inc | 148 | $146,842 |
| AbbVie(2 entities) | 122 | $119,924 |
| Indivior Inc. | 50 | $74,793 |
| Vanda Pharmaceuticals Inc. | 34 | $36,637 |
| Boehringer Ingelheim | 21 | $22,146 |
| Boehringer Ingelheim International GmbH | 13 | $19,907 |
| Sunovion Pharmaceuticals Inc. | 35 | $15,186 |
| Eisai Inc. | 23 | $13,812 |
| Noven Pharmaceuticals, Inc. | 13 | $13,276 |
| Livanova USA, Inc. | 5 | $7,780 |
| Avanir Pharmaceuticals, Inc. | 2 | $3,100 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $3,029 |
| Luye Pharma (USA) Ltd. | 1 | $121 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$686,605
- INVEGA TRINZA$681,933
- ARISTADA$612,491
- INGREZZA$478,948
- LYBALVI$456,583
- CAPLYTA$407,173
- ABILIFY MAINTENA$406,013
- UZEDY$356,883
- Auvelity$287,084
- ABILIFY ASIMTUFII$227,514
- NUPLAZID$142,430
- ARISTADA INITIO$132,688
- VRAYLAR$118,017
- COBENFY$95,282
- AUSTEDO$93,650
- PERSERIS$74,146
- Austedo XR$61,879
- Fanapt$36,235
- LATUDA$13,668
- SECUADO$13,276
How this compares
$3,769,307 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Cincinnati
- Caleb AdlerCincinnati$2M
- Paul KeckCincinnati$739K
- Peter BoxerCincinnati$718K
- Tracey SkaleCincinnati$674K
- Lesley ArnoldCincinnati$620K
- Stephen PolandCincinnati$440K
- Fabiano NeryCincinnati$391K
- Jeffrey StrawnCincinnati$336K
- Helen FarrellCincinnati$277K
- Janell LundgrenCincinnati$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.